Cite
Real-World Evidence of Treatment, Tolerance, Healthcare Utilization, and Costs Among Postacute Care Adult Patients Receiving Enteral Peptide-Based Diets in the United States.
MLA
LaVallee, Chris, et al. “Real-World Evidence of Treatment, Tolerance, Healthcare Utilization, and Costs Among Postacute Care Adult Patients Receiving Enteral Peptide-Based Diets in the United States.” JPEN. Journal of Parenteral and Enteral Nutrition, vol. 45, no. 8, Nov. 2021, pp. 1729–35. EBSCOhost, https://doi.org/10.1002/jpen.2074.
APA
LaVallee, C., Seelam, P., Balakrishnan, S., Lowen, C., Henrikson, A., Kesting, B., Perugini, M., & Araujo Torres, K. (2021). Real-World Evidence of Treatment, Tolerance, Healthcare Utilization, and Costs Among Postacute Care Adult Patients Receiving Enteral Peptide-Based Diets in the United States. JPEN. Journal of Parenteral and Enteral Nutrition, 45(8), 1729–1735. https://doi.org/10.1002/jpen.2074
Chicago
LaVallee, Chris, Prafullakumar Seelam, Santosh Balakrishnan, Cynthia Lowen, Aimee Henrikson, Bill Kesting, Moreno Perugini, and Krysmaru Araujo Torres. 2021. “Real-World Evidence of Treatment, Tolerance, Healthcare Utilization, and Costs Among Postacute Care Adult Patients Receiving Enteral Peptide-Based Diets in the United States.” JPEN. Journal of Parenteral and Enteral Nutrition 45 (8): 1729–35. doi:10.1002/jpen.2074.